Literature DB >> 22778391

Attenuation of acute graft-versus-host disease in the absence of the transcription factor RORγt.

LeShara M Fulton1, Michael J Carlson, James M Coghill, Laura E Ott, Michelle L West, Angela Panoskaltsis-Mortari, Dan R Littman, Bruce R Blazar, Jonathan S Serody.   

Abstract

Graft-versus-host disease (GVHD) remains the most significant complication after allogeneic stem cell transplantation. Previously, acute GVHD had been considered to be mediated predominantly by Th1-polarized T cells. Recently, investigators have identified a second proinflammatory lineage of T cells termed Th17 that is critically dependent on the transcription factor retinoic acid-related orphan receptor (ROR)γt. In this study, we have evaluated the role of Th17 cells in murine acute GVHD by infusing donor T cells lacking RORC and as a consequence the isoform RORγt. Recipients given donor CD4(+) and CD8(+) T cells lacking RORC had significantly attenuated acute GVHD and markedly decreased tissue pathology in the colon, liver, and lung. Using a clinically relevant haploidentical murine transplantation model, we showed that RORC(-/-) CD4(+) T cells alone diminished the severity and lethality of acute GVHD. This was not found when CD4(+) T cells from RORC(-/-) mice were given to completely mismatched BALB/c mice, and it was correlated with absolute differences in the generation of TNF in the colon after transplant. Thus, CD4(+) T cell expression of RORC is important in the pathogenesis of acute GVHD.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22778391      PMCID: PMC3411855          DOI: 10.4049/jimmunol.1200858

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  37 in total

1.  Differential roles for CCR5 expression on donor T cells during graft-versus-host disease based on pretransplant conditioning.

Authors:  Christian A Wysocki; Susan B Burkett; Angela Panoskaltsis-Mortari; Suzanne L Kirby; Andrew D Luster; Karen McKinnon; Bruce R Blazar; Jonathan S Serody
Journal:  J Immunol       Date:  2004-07-15       Impact factor: 5.422

Review 2.  Allogenic bone marrow transplantation for leukemias and aplastic anemia.

Authors:  T W Tsai; C O Freytes
Journal:  Adv Intern Med       Date:  1997

Review 3.  Stem cell transplantation in acute leukemia.

Authors:  S J Forman
Journal:  Curr Opin Oncol       Date:  1998-01       Impact factor: 3.645

4.  Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon.

Authors:  K Hori; M J Ehrke; K Mace; E Mihich
Journal:  Cancer Res       Date:  1987-11-15       Impact factor: 12.701

5.  Quantitative analysis of T helper 1, T helper 2, and inflammatory cytokine expression in patients after allogeneic bone marrow transplantation: relationship with the occurrence of acute graft-versus-host disease.

Authors:  G Carayol; J H Bourhis; M Guillard; J Bosq; C Pailler; L Castagna; J P Vernant; J L Pico; M Hayat; S Chouaib; A Caignard
Journal:  Transplantation       Date:  1997-05-15       Impact factor: 4.939

Review 6.  Biology of interleukin-22.

Authors:  Kerstin Wolk; Ellen Witte; Katrin Witte; Katarzyna Warszawska; Robert Sabat
Journal:  Semin Immunopathol       Date:  2010-02-02       Impact factor: 9.623

7.  Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via In utero or postnatal transfer.

Authors:  B R Blazar; P A Taylor; R McElmurry; L Tian; A Panoskaltsis-Mortari; S Lam; C Lees; T Waldschmidt; D A Vallera
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

8.  Differential effects of the absence of interferon-gamma and IL-4 in acute graft-versus-host disease after allogeneic bone marrow transplantation in mice.

Authors:  W J Murphy; L A Welniak; D D Taub; R H Wiltrout; P A Taylor; D A Vallera; M Kopf; H Young; D L Longo; B R Blazar
Journal:  J Clin Invest       Date:  1998-11-01       Impact factor: 14.808

9.  Serum cytokine levels in bone marrow transplantation: synergistic interaction of interleukin-6, interferon-gamma, and tumor necrosis factor-alpha in graft-versus-host disease.

Authors:  M Imamura; S Hashino; H Kobayashi; S Kubayashi; S Hirano; T Minagawa; J Tanaka; Y Fujii; M Kobayashi; M Kasai
Journal:  Bone Marrow Transplant       Date:  1994-06       Impact factor: 5.483

Review 10.  Graft-versus-host disease: emerging concepts in prevention and therapy.

Authors:  Robert M Dean; Michael R Bishop
Journal:  Curr Hematol Rep       Date:  2003-07
View more
  31 in total

1.  Altered T-cell entry and egress in the absence of Coronin 1A attenuates murine acute graft versus host disease.

Authors:  LeShara M Fulton; Nicholas A Taylor; James M Coghill; Michelle L West; Niko Föger; James E Bear; Albert S Baldwin; Angela Panoskaltsis-Mortari; Jonathan S Serody
Journal:  Eur J Immunol       Date:  2014-06       Impact factor: 5.532

2.  CD4+ T cell STAT3 phosphorylation precedes acute GVHD, and subsequent Th17 tissue invasion correlates with GVHD severity and therapeutic response.

Authors:  Brian C Betts; Elizabeth M Sagatys; Anandharaman Veerapathran; Mark C Lloyd; Francisca Beato; Harshani R Lawrence; Binglin Yue; Jongphil Kim; Said M Sebti; Claudio Anasetti; Joseph Pidala
Journal:  J Leukoc Biol       Date:  2015-02-06       Impact factor: 4.962

3.  IL-17A ≠ Th17 in GvHD.

Authors:  Yongxia Wu; Xue-Zhong Yu
Journal:  Cell Mol Immunol       Date:  2016-10-31       Impact factor: 11.530

Review 4.  Essentials of Th17 cell commitment and plasticity.

Authors:  Pawel Muranski; Nicholas P Restifo
Journal:  Blood       Date:  2013-01-16       Impact factor: 22.113

5.  Adoptively transferred donor IL-17-producing CD4+ T cells augment, but IL-17 alleviates, acute graft-versus-host disease.

Authors:  Yifeng Cai; Shoubao Ma; Yuejun Liu; Huanle Gong; Qiao Cheng; Bo Hu; Yan Wu; Xiao Yu; Chen Dong; Kai Sun; Depei Wu; Haiyan Liu
Journal:  Cell Mol Immunol       Date:  2016-10-17       Impact factor: 11.530

6.  Intravital imaging of donor allogeneic effector and regulatory T cells with host dendritic cells during GVHD.

Authors:  Kaifeng Lisa Lin; LeShara M Fulton; Matthew Berginski; Michelle L West; Nicholas A Taylor; Timothy P Moran; James M Coghill; Bruce R Blazar; James E Bear; Jonathan S Serody
Journal:  Blood       Date:  2014-01-10       Impact factor: 22.113

7.  Systems analysis uncovers inflammatory Th/Tc17-driven modules during acute GVHD in monkey and human T cells.

Authors:  Scott N Furlan; Benjamin Watkins; Victor Tkachev; Sarah Cooley; Angela Panoskaltsis-Mortari; Kayla Betz; Melanie Brown; Daniel J Hunt; John B Schell; Katie Zeleski; Alison Yu; Cynthia R Giver; Edmund K Waller; Jeffrey S Miller; Bruce R Blazar; Leslie S Kean
Journal:  Blood       Date:  2016-10-06       Impact factor: 22.113

8.  Proteomics analysis reveals a Th17-prone cell population in presymptomatic graft-versus-host disease.

Authors:  Wei Li; Liangyi Liu; Aurelie Gomez; Jilu Zhang; Abdulraouf Ramadan; Qing Zhang; Sung W Choi; Peng Zhang; Joel K Greenson; Chen Liu; Di Jiang; Elizabeth Virts; Stephanie L Kelich; Hong Wei Chu; Ryan Flynn; Bruce R Blazar; Helmut Hanenberg; Samir Hanash; Sophie Paczesny
Journal:  JCI Insight       Date:  2016-05-05

9.  BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-versus-host disease.

Authors:  Evelyn Ullrich; Benjamin Abendroth; Johanna Rothamer; Carina Huber; Maike Büttner-Herold; Vera Buchele; Tina Vogler; Thomas Longerich; Sebastian Zundler; Simon Völkl; Andreas Beilhack; Stefan Rose-John; Stefan Wirtz; Georg F Weber; Sakhila Ghimire; Marina Kreutz; Ernst Holler; Andreas Mackensen; Markus F Neurath; Kai Hildner
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

10.  Newly found arsons ignite the fire of gut GVHD.

Authors:  Defu Zeng
Journal:  J Clin Invest       Date:  2018-01-29       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.